VMAT2 and Parkinson's Disease: Harnessing the Dopamine Vesicle

Overview

Journal Expert Rev Neurother

Specialties Neurology
Pharmacology

Date 2014 Sep 16

PMID 25220836

Citations 23

Authors

Kelly M Lohr

Gary W Miller

Affiliations

Soon will be listed here.

Abstract

Despite a movement away from dopamine-focused Parkinson's disease (PD) research, a recent surge of evidence now suggests that altered vesicular storage of dopamine may contribute to the demise of the nigral neurons in this disease. Human studies demonstrate that the vesicular monoamine transporter 2 (VMAT2; SLC18A2) is dysfunctional in PD brain. Moreover, studies with transgenic mice suggest that there is an untapped reserve capacity of the dopamine vesicle that could be unbridled by increasing VMAT2 function. Therapeutic manipulation of VMAT2 level or function has the potential to improve efficacy of dopamine derived from administered levodopa, increase dopamine neurotransmission from remaining midbrain dopamine neurons and protect against neurotoxic insults. Thus, the development of drugs to enhance the storage of release of dopamine may be a fruitful avenue of research for PD.

Citing Articles

Modified human mesenchymal stromal/stem cells restore cortical excitability after focal ischemic stroke in rats.

Klein B, Ciesielska A, Losada P, Sato A, Shah-Morales S, Ford J Mol Ther. 2024; 33(1):375-400.

PMID: 39668560 PMC: 11764858. DOI: 10.1016/j.ymthe.2024.12.006.

Structural insights into vesicular monoamine storage and drug interactions.

Ye J, Chen H, Wang K, Wang Y, Ammerman A, Awasthi S Nature. 2024; 629(8010):235-243.

PMID: 38499039 PMC: 11070986. DOI: 10.1038/s41586-024-07290-7.

Transcriptomic profiling of early synucleinopathy in rats induced with preformed fibrils.

Patterson J, Kochmanski J, Stoll A, Kubik M, Kemp C, Duffy M NPJ Parkinsons Dis. 2024; 10(1):7.

PMID: 38172128 PMC: 10764951. DOI: 10.1038/s41531-023-00620-y.

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions.

Alwindi M, Bizanti A Heliyon. 2023; 9(11):e22413.

PMID: 38034713 PMC: 10687066. DOI: 10.1016/j.heliyon.2023.e22413.

Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC-H 106.

Lee H, Kim H, Choi D, Ko E, Choi J, Seo Y Pharmacol Res Perspect. 2023; 11(5):e01135.

PMID: 37740715 PMC: 10517640. DOI: 10.1002/prp2.1135.

References

Schuldiner S, Shirvan A, Linial M . Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev. 1995; 75(2):369-92. DOI: 10.1152/physrev.1995.75.2.369. View

Takahashi N, Miner L, Sora I, Ujike H, Revay R, Kostic V . VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A. 1997; 94(18):9938-43. PMC: 23302. DOI: 10.1073/pnas.94.18.9938. View

Rilstone J, Alkhater R, Minassian B . Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med. 2013; 368(6):543-50. DOI: 10.1056/NEJMoa1207281. View

Wang Y, Gainetdinov R, Fumagalli F, Xu F, Jones S, Bock C . Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron. 1998; 19(6):1285-96. DOI: 10.1016/s0896-6273(00)80419-5. View

Liu Y, EDWARDS R . The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci. 1997; 20:125-56. DOI: 10.1146/annurev.neuro.20.1.125. View

Sulzer D, Zecca L . Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res. 2003; 1(3):181-95. DOI: 10.1007/BF03033289. View

Lohr K, Bernstein A, Stout K, Dunn A, Lazo C, Alter S . Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2014; 111(27):9977-82. PMC: 4103325. DOI: 10.1073/pnas.1402134111. View

Brighina L, Riva C, Bertola F, Saracchi E, Fermi S, Goldwurm S . Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease. Neurobiol Aging. 2013; 34(6):1712.e9-13. PMC: 3605583. DOI: 10.1016/j.neurobiolaging.2012.12.020. View

Guillot T, Miller G . Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol. 2009; 39(2):149-70. DOI: 10.1007/s12035-009-8059-y. View

10.

Ahlskog J . Beating a dead horse: dopamine and Parkinson disease. Neurology. 2007; 69(17):1701-11. DOI: 10.1212/01.wnl.0000296942.14309.4a. View

11.

Ehringer H, Hornykiewicz O . [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960; 38:1236-9. DOI: 10.1007/BF01485901. View

12.

Glatt C, Wahner A, White D, Ruiz-Linares A, Ritz B . Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet. 2005; 15(2):299-305. PMC: 3643966. DOI: 10.1093/hmg/ddi445. View

13.

Goldstein D, Sullivan P, Holmes C, Miller G, Alter S, Strong R . Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem. 2013; 126(5):591-603. PMC: 4096629. DOI: 10.1111/jnc.12345. View

14.

Liu Y, Peter D, Roghani A, Schuldiner S, Prive G, Eisenberg D . A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell. 1992; 70(4):539-51. DOI: 10.1016/0092-8674(92)90425-c. View

15.

Caudle W, Richardson J, Wang M, Taylor T, Guillot T, McCormack A . Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci. 2007; 27(30):8138-48. PMC: 6672727. DOI: 10.1523/JNEUROSCI.0319-07.2007. View

16.

Fon E, Pothos E, Sun B, Killeen N, Sulzer D, EDWARDS R . Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron. 1998; 19(6):1271-83. DOI: 10.1016/s0896-6273(00)80418-3. View

17.

Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso J . Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci. 2014; 34(24):8210-8. PMC: 6608236. DOI: 10.1523/JNEUROSCI.5456-13.2014. View